Brief: Kaleido Biosciences Inc - Kb174 Exceeded Targeted Reduction In A Biomarker Of Microbiome Ammonia Production
12/12/2019 14:08
Kaleido Biosciences Inc KLDO.O :
* KALEIDO BIOSCIENCES TO ADVANCE KB174 FOR HEPATIC
ENCEPHALOPATHY
BASED ON POSITIVE TOP-LINE RESULTS FROM A CLINICAL STUDY IN
PATIENTS WITH CIRRHOSIS
* KALEIDO BIOSCIENCES INC - KB174 EXCEEDED TARGETED
REDUCTION IN A
BIOMARKER OF MICROBIOME AMMONIA PRODUCTION
* KALEIDO BIOSCIENCES INC - KB174 WAS WELL TOLERATED AND NO
CLINICALLY SIGNIFICANT OR SERIOUS TREATMENT-RELATED ADVERSE
EVENTS WERE OBSERVED
Source text for Eikon: ID:nGNXYpKK5
Further company coverage: KLDO.O